In line with our finding that CD155, the ligand for TIGIT, is reliably expressed on AML blasts, TIGIT-blockade significantly promoted the functionality of NK-92 cells, but surprisingly not of CIML-NK cells toward the CD155-expressing AML cell lines Molm-13 and HL-60. Here, PVR is linked to acute myeloid leukemia.